Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Lyell Immunopharma, Inc. (NASDAQ: LYEL)
LYEL Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
198.70%
LYEL Stock Analysis
LYEL
PE Ratio:
LYEL
PEG Ratio:
Not Available
LYEL
Forward EPS Growth (12 month):
0.00%
LYEL
PS Ratio:
10138.3
LYEL
PSG Ratio:
25.3
LYEL
Forward Revenue Growth (12 month):
400.00%
LYEL Articles
No data was found